Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07179380 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
A Phase 3 study of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by Insmed Incorporated.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
- 20
- Study locations
NCT07179380 is a Phase 3 study of Pulmonary Hypertension and Interstitial Lung Disease that is actively recruiting participants, run by Insmed Incorporated. The registered enrollment target is 344 participants, below the 609-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT07179380, a Phase 3 study of Pulmonary Hypertension and Interstitial Lung Disease, is actively recruiting participants, sponsored by Insmed Incorporated.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Treprostinil Palmitil Inhalation Powder
Study Locations (20)
Other
- GEO002 - Tbilisi
- GEO004 - Tbilisi
- GEO003 - Tbilisi
- GEO001 - Tbilisi
- DEU010 - Gauting
- ISR001 - Haifa
- ISR002 - Jerusalem
- ISR004 - Tel Aviv
Chiba
- JPN002 - Narashino-shi
- JPN004 - Narita
California
- USA001 - Santa Barbara
Florida
- USA006 - Naples
Oregon
- USA003 - Bend
Virginia
- USA008 - Richmond
Bavaria
- DEU003 - München
Hesse
- DEU005 - Immenhausen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2026-01-07 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07179380
The ClinicalTrials.gov registry entry for NCT07179380 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (44% lower). The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07179380 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Chiba, California.
Frequently Asked Questions
What is clinical trial NCT07179380 about?
NCT07179380 is a clinical study titled "Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)". The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
What is the current status of trial NCT07179380?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2026-01-07. Estimated completion is 2028-12-30.
What conditions does trial NCT07179380 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Interstitial Lung Disease.
What interventions are being tested in trial NCT07179380?
The interventions under investigation include: Placebo (DRUG), Treprostinil Palmitil Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT07179380?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07179380 being conducted?
This trial has 20 study locations across California, Florida, Oregon, Virginia, Bavaria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Safety and Efficacy of FETO in CDH Phase III
RECRUITING · Phase 3
-
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
COMPLETED · Phase 3
-
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
COMPLETED · Phase 3
-
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
COMPLETED · Phase 3
-
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.